Discovery and Biological Evaluation of a Novel Highly Potent Selective Butyrylcholinsterase Inhibitor
作者:Qi Li、Shuaishuai Xing、Ying Chen、Qinghong Liao、Baichen Xiong、Siyu He、Weixuan Lu、Yang Liu、Hongyu Yang、Qihang Li、Feng Feng、Wenyuan Liu、Yao Chen、Haopeng Sun
DOI:10.1021/acs.jmedchem.0c01129
日期:2020.9.10
to the normal level and showed better behavioral performance than donepezil. The evaluation of the Aβ1–42 total amount confirmed its anti-amyloidogenic profile. Moreover, 8012-9656 possessed blood–brain barrier (BBB) penetrating ability, a long T1/2, and low intrinsic clearance. Hence, the novel potential BChE inhibitor 8012-9656 can be considered as a promising lead compound for further investigation
为了发现新型的BChE抑制剂,应用了分级虚拟筛选方案,然后进行了生化评估。购买并合成了最有效的化合物8012-9656(eq BChE IC 50 = 0.18± 0.03μM,h BChE IC 50 = 0.32±0.07μM)。它以非竞争性方式抑制BChE,并可能占据结合袋,与靶标形成多种相互作用。事实证明8012-9656在体内和体外都是安全的,并且在减轻东pol碱引起的他克林认知障碍方面表现出可比的性能。此外,用8012-9656处理几乎可以完全恢复Aβ1–42(icv)使认知功能受损至正常水平,并且表现出比多奈哌齐更好的行为表现。Aβ1–42总量的评估证实了其抗淀粉样蛋白形成的特性。此外,8012-9656具有穿透血脑屏障(BBB)的能力,长T 1/2和低内在清除率。因此,新型潜在的BChE抑制剂8012-9656可被认为是抗AD药物进一步研究的有前途的先导化合物。